Last updated: August 24, 2026
Glipizide and metformin hydrochloride is a mature, low-cost generic combination for type 2 diabetes. Its commercial profile is defined by high clinical familiarity, broad generic availability, limited pricing power, and substitution by newer therapies such as SGLT2 inhibitors, GLP-1 receptor agonists, and fixed-dose combinations involving metformin.
The branded product, Metaglip, no longer drives the market. Current value is distributed across generic manufacturers, wholesalers, retail pharmacies, Medicaid programs, Medicare Part D plans, and international markets. Public companies generally do not report revenue for this product separately, so financial analysis depends on prescription volume, market-share data, unit pricing, and manufacturer filings.
What is glipizide and metformin hydrochloride used for?
Glipizide and metformin hydrochloride is an oral fixed-dose combination used with diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. It combines:
- Glipizide, a sulfonylurea that stimulates pancreatic insulin secretion.
- Metformin hydrochloride, a biguanide that reduces hepatic glucose production and improves insulin sensitivity.
The combination was designed for patients whose glycemic control was inadequate with either component alone. It is not used for type 1 diabetes or diabetic ketoacidosis.
Common tablet strengths include:
| Glipizide |
Metformin hydrochloride |
| 2.5 mg |
250 mg |
| 2.5 mg |
500 mg |
| 5 mg |
500 mg |
| 5 mg |
1,000 mg in some markets and formulations |
The product has a lower acquisition cost than most branded diabetes therapies. Its clinical limitations include hypoglycemia risk from glipizide, gastrointestinal effects from metformin, weight gain associated with sulfonylureas, and renal restrictions applicable to metformin.
What is the FDA status of glipizide and metformin hydrochloride?
The branded combination Metaglip received FDA approval in the early 2000s under Bristol-Myers Squibb. The product was later discontinued in the United States for commercial reasons rather than because of an FDA determination that it was unsafe or ineffective. Generic versions remain available through abbreviated new drug applications and are regulated under the FDA’s generic-drug framework.[1][2]
The key regulatory characteristics are:
| Regulatory issue |
Current commercial effect |
| FDA pathway |
Abbreviated new drug application for generic products |
| Reference product |
Metaglip |
| Therapeutic area |
Type 2 diabetes |
| Regulatory status |
Mature generic market |
| Brand commercial role |
Minimal or absent in the U.S. |
| Prescribing channel |
Retail, mail-order, managed care, and government programs |
| Main substitution risk |
Separate generic components and newer diabetes therapies |
The product is not a biologic and does not face biosimilar competition. Its competitive risk comes from generic substitution and therapeutic substitution.
What is the Orange Book status of glipizide and metformin hydrochloride?
The Orange Book treatment of the product is primarily relevant to the historical reference product, Metaglip, and to the generic approval pathway. The commercial opportunity is not protected by a meaningful current branded exclusivity period.
The product’s market has passed the period in which patents or regulatory exclusivity could support premium pricing. Generic applicants can generally rely on the reference product’s safety and efficacy findings through the ANDA pathway, subject to bioequivalence and applicable labeling requirements.[2][3]
The practical Orange Book conclusions are:
- Metaglip is a legacy reference product rather than an active premium brand.
- Any historical brand exclusivity has expired.
- Current generic competition is driven by ANDA approvals, manufacturing capacity, contracting, and supply reliability.
- Product-level patent disputes are less commercially important than manufacturing and pricing competition.
A definitive patent-expiration analysis would require a defined jurisdiction, product strength, dosage form, and reference-product listing. The U.S. commercial market does not depend on an unexpired composition-of-matter patent for the combination.
What patents protect glipizide and metformin hydrochloride?
The active ingredients are long-established small molecules with expired basic patent protection. The relevant intellectual-property categories historically included:
- The individual active ingredients.
- Combination composition claims.
- Tablet formulations.
- Manufacturing processes.
- Crystalline or salt forms.
- Dosing and administration methods.
For the current U.S. generic market, these categories do not create a durable exclusionary position comparable to a modern branded diabetes product. Formulation patents, if present in particular jurisdictions or historical product records, would be narrow and would not normally prevent broad competition in standard immediate-release tablets.
What formulations are protected?
The commercially important dosage form is the immediate-release oral tablet. Some manufacturers may hold or have held process or formulation rights involving:
- Granulation methods.
- Excipients and tablet hardness.
- Stability improvement.
- Modified release.
- Combination-tablet manufacturing.
These rights have limited market impact unless they cover the only commercially viable formulation or create a regulatory barrier to substitution. Standard immediate-release generic tablets are generally replaceable through multiple suppliers.
Extended-release metformin products compete with the fixed immediate-release combination but are not necessarily substitutable on a milligram-for-milligram basis without prescriber or pharmacist review.
When does glipizide and metformin lose exclusivity?
The product lost commercially meaningful exclusivity years ago. Metaglip’s market position was eroded by generic entry, the expiration of historical protection, and the availability of the two ingredients as inexpensive separate tablets.
There is no remaining branded exclusivity period that is likely to restore premium pricing in the United States. The relevant commercial timeline is:
| Period |
Market event |
Financial effect |
| Early 2000s |
FDA approval of Metaglip |
Created a branded fixed-dose combination |
| Mid-to-late 2000s |
Generic competition emerged |
Reduced brand pricing power |
| 2010s |
Brand discontinuation and mature generic supply |
Shifted revenue to generic manufacturers |
| 2020s |
Continued generic use with newer-agent substitution |
Stable volume but persistent price pressure |
The principal exclusivity issue today is not patent expiry. It is whether a manufacturer can maintain an approved, competitively priced, and reliably supplied product.
How many patents cover glipizide and metformin hydrochloride?
No single active U.S. patent estate controls the current standard generic market for glipizide and metformin hydrochloride. Historical patents may have covered the combination, specific formulations, or manufacturing processes, but those rights do not create a broad current monopoly.
Patent strength is therefore low from an investment perspective:
| Patent factor |
Assessment |
| Composition-of-matter protection |
Expired |
| Branded combination protection |
Historical and commercially exhausted |
| Formulation protection |
Potentially narrow and jurisdiction-specific |
| Method-of-use protection |
Limited practical value in a generic indication |
| Manufacturing patents |
Possible, but unlikely to block the market |
| Litigation leverage |
Low |
| Generic entry barrier |
Low |
Which companies are challenging the branded product?
The market is no longer characterized by a small number of Paragraph IV challengers targeting an active branded franchise. Generic manufacturers have entered through ordinary ANDA competition and compete on price, supply continuity, contract access, and regulatory compliance.
Potential suppliers in the broader U.S. oral diabetes generic market include major generic companies such as:
- Teva Pharmaceutical Industries.
- Viatris.
- Dr. Reddy’s Laboratories.
- Lupin.
- Zydus Pharmaceuticals.
- Amneal Pharmaceuticals.
- Torrent Pharmaceuticals.
- ANI Pharmaceuticals.
- Smaller regional and contract manufacturers.
Availability varies by strength, package size, wholesaler, and time period. A manufacturer may have an approved ANDA but limited commercial distribution.
What generic entry risks exist for glipizide and metformin hydrochloride?
Generic entry risk is already realized rather than prospective. The product has low barriers to entry because:
- The active ingredients are chemically established.
- The indication and labeling are well understood.
- Bioequivalence requirements are manageable for immediate-release tablets.
- The reference product has a long regulatory history.
- Prescribers and pharmacists are familiar with both components.
- The product can be substituted by separate generic tablets.
The remaining risk is a further decline in price and volume as payers favor other low-cost regimens or newer agents with outcome-based benefits.
What Paragraph IV risks exist?
Paragraph IV litigation is unlikely to be a major current market event for the standard product. A Paragraph IV certification could arise against a listed patent associated with a reference product, but the commercial value of such a challenge would be limited where:
- The reference brand is discontinued.
- The product has no meaningful premium price.
- Multiple generic suppliers already exist.
- The alleged patent does not cover all clinically interchangeable alternatives.
The absence of an active high-value brand reduces the incentive to finance aggressive patent litigation.
How does the product compare with newer diabetes drugs?
Glipizide and metformin hydrochloride competes on cost, not on cardiovascular, renal, weight-loss, or hypoglycemia performance.
| Treatment |
Main advantage |
Main limitation versus the combination |
| Glipizide/metformin |
Very low cost and familiar oral dosing |
Hypoglycemia and weight-gain risk |
| Metformin alone |
Lower cost and simpler regimen |
May provide inadequate control alone |
| SGLT2 inhibitor plus metformin |
Cardiovascular and renal benefits in selected patients |
Higher cost and broader adverse-effect considerations |
| GLP-1 receptor agonist |
Strong glucose lowering and weight reduction |
Injectable or specialized oral products; high cost |
| DPP-4 inhibitor plus metformin |
Low hypoglycemia risk and oral administration |
Higher cost; less weight loss |
| Insulin-based therapy |
Powerful glucose lowering |
Hypoglycemia, monitoring, and administration burden |
Clinical guidelines increasingly prioritize agents with cardiovascular, renal, or weight-related benefits for patients with relevant comorbidities. That trend limits long-term growth for sulfonylurea-containing combinations, even when the product remains useful for cost-sensitive patients.[4]
What is the financial trajectory for glipizide and metformin hydrochloride?
The financial trajectory is mature-to-declining in value, with relatively durable but pressured unit demand.
Revenue profile
No major manufacturer publicly reports a material standalone revenue line for glipizide and metformin hydrochloride. The product is generally included within broader generic portfolios. Its financial profile has four characteristics:
- Brand revenue has largely disappeared.
- Generic unit volume remains supported by diabetes prevalence.
- Net pricing is low and subject to payer and wholesaler pressure.
- Manufacturer profitability depends on scale and manufacturing efficiency.
The U.S. product is unlikely to generate meaningful royalty or licensing income because the branded franchise has passed its exclusivity period. International sales may be more relevant for companies with strong emerging-market distribution, but unit economics remain sensitive to local procurement systems and tender pricing.
Demand drivers
Demand is supported by:
- High global prevalence of type 2 diabetes.
- Continued use of low-cost oral therapy.
- Public-sector and Medicaid cost controls.
- Patients unable to access newer branded therapies.
- Familiarity among primary-care prescribers.
- Use in markets where newer agents remain unaffordable.
Demand constraints
Demand is constrained by:
- Substitution with metformin alone.
- Use of separate generic glipizide and metformin tablets.
- Migration to SGLT2 inhibitors and GLP-1 therapies.
- Sulfonylurea-associated hypoglycemia concerns.
- Weight-gain concerns.
- Renal-function restrictions on metformin.
- Fixed-dose combinations involving other diabetes classes.
What manufacturing and supply-chain barriers affect the market?
Manufacturing barriers are operational rather than technological. The product requires reliable sourcing of both active pharmaceutical ingredients, validated combination-tablet processes, stability testing, and compliance with current good manufacturing practice requirements.
Supply risks can arise from:
- Active ingredient shortages.
- FDA warning letters or facility inspections.
- Reliance on a single manufacturing site.
- Packaging and serialization failures.
- Contract-manufacturing disruptions.
- Low margins that cause suppliers to exit.
- Wholesaler consolidation and inventory rationalization.
A supplier with multiple approved sites and strong retail-pharmacy contracts can maintain share even without patent protection. Conversely, a small supplier can lose access quickly if it experiences a quality event or cannot meet price targets.
What litigation and settlement agreements affect the product?
There is no widely recognized active U.S. litigation campaign comparable to disputes involving high-revenue branded diabetes drugs. Historical patent litigation may have accompanied generic entry, but the present market is primarily governed by regulatory approval, supply, and commercial contracting.
Settlement agreements have limited strategic importance where:
- The reference product is discontinued.
- The product is already genericized.
- No high-value patent term remains.
- Multiple suppliers compete across the same strengths.
The more material legal risks are product-liability claims, manufacturing compliance actions, antitrust scrutiny of generic pricing, and contract disputes rather than exclusivity litigation.
What is the geographic coverage of the product market?
Glipizide and metformin hydrochloride has broader commercial relevance in price-sensitive markets than in high-income markets that have rapidly adopted newer diabetes agents.
The United States remains a regulated generic market with low unit prices and payer-driven substitution. In emerging markets, fixed-dose combinations can retain stronger demand because they reduce pill burden and improve affordability. Pricing, registration status, local manufacturing rules, and government procurement determine country-level opportunity.
A manufacturer seeking international expansion would need to manage:
- Country-specific registration.
- Local bioequivalence requirements.
- Pharmacovigilance obligations.
- Public tender pricing.
- Import controls.
- Local labeling and language requirements.
- Reference-pricing systems.
Key Takeaways
- Glipizide and metformin hydrochloride is a mature generic type 2 diabetes product.
- Metaglip no longer provides a meaningful branded commercial platform in the United States.
- Basic patent protection has expired, and current market barriers are operational rather than intellectual-property based.
- Generic entry risk is fully realized, with competition focused on price, supply, and payer access.
- Revenue is fragmented and generally not disclosed separately by manufacturers.
- Volume is supported by diabetes prevalence and affordability needs.
- Long-term value is pressured by SGLT2 inhibitors, GLP-1 receptor agonists, DPP-4 inhibitors, and metformin-based alternatives.
- The strongest commercial position belongs to manufacturers with efficient production, dependable supply, broad distribution, and low regulatory risk.
FAQs
Is glipizide and metformin hydrochloride still commercially viable?
Yes, but primarily as a low-cost generic product. Its viability depends on manufacturing scale and supply reliability rather than patent protection or premium pricing.
Can glipizide and metformin be replaced with separate tablets?
Often, clinicians can prescribe the same active ingredients separately, but the dosage, adherence profile, titration schedule, and insurance coverage must be reviewed before substitution.
Does glipizide and metformin hydrochloride have biosimilar competition?
No. Both ingredients are small-molecule drugs, so the relevant competition is from generic drugs, not biosimilars.
Is the combination attractive for pharmaceutical licensing?
It generally has limited licensing value in the United States because exclusivity has expired, generic prices are low, and no major branded revenue stream remains. Licensing may be more relevant for regional distribution, contract manufacturing, or emerging-market registrations.
What would cause a sudden change in product economics?
The main catalysts would be a major supply shortage, a large manufacturer withdrawal, a regulatory action, a payer policy change, or a significant shift in diabetes-treatment guidelines. Patent-driven price expansion is unlikely.
References
-
U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs. https://www.accessdata.fda.gov/scripts/cder/daf/
-
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book
-
U.S. Food and Drug Administration. (n.d.). Abbreviated new drug application (ANDA): Generics. https://www.fda.gov/drugs/types-applications/abbreviated-new-drug-application-anda
-
American Diabetes Association Professional Practice Committee. (2024). 9. Pharmacologic approaches to glycemic treatment: Standards of care in diabetes - 2024. Diabetes Care, 47(Supplement_1), S158-S178. https://doi.org/10.2337/dc24-S009
